Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Trial of Alpha-Tocopheryloxyacetic Acid (α-TEA) in Patients With Treatment Refractory HER2+ Metastatic Breast Cancer

NCT04120246 is registered in ClinicalTrials.gov with Veana Therapeutics as lead sponsor.

NCT NCT04120246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04120246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Trial of Alpha-Tocopheryloxyacetic Acid (α-TEA) in Patients With Treatment Refractory HER2+ Metastatic Breast Cancer
Lead sponsor
Veana Therapeutics
Phase
Phase 1
Overall status
Suspended
Start date
April 8, 2020
Completion date
February 1, 2030
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, her2 positive breast carcinoma, metastatic breast carcinoma, refractory breast carcinoma